<DOC>
	<DOCNO>NCT01277328</DOCNO>
	<brief_summary>This observational , prospective , open-label , multi-center study evaluate effectiveness disease reduction safety RoActemra/Actemra ( tocilizumab ) patient rheumatoid arthritis . Data collect 11 month .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient &gt; /=18 year age Patients rheumatoid arthritis eligible RoActemra Hypersensitivity RoActemra Active , severe infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>